- Home
- KPRX vs GXAI Comparison
KPRX vs GXAI Comparison
Compare KPRX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- GXAI
- Stock Information
- Founded
- KPRX 1998
- GXAI 2021
- Country
- KPRX United States
- GXAI United States
- Employees
- KPRX N/A
- GXAI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GXAI
- Sector
- KPRX Health Care
- GXAI
- Exchange
- KPRX Nasdaq
- GXAI Nasdaq
- Market Cap
- KPRX 9.1M
- GXAI 10.1M
- IPO Year
- KPRX N/A
- GXAI 2023
- Fundamental
- Price
- KPRX $2.90
- GXAI $1.45
- Analyst Decision
- KPRX Strong Buy
- GXAI
- Analyst Count
- KPRX 1
- GXAI 0
- Target Price
- KPRX $10.00
- GXAI N/A
- AVG Volume (30 Days)
- KPRX 1.3M
- GXAI 113.0K
- Earning Date
- KPRX 08-08-2025
- GXAI 08-12-2025
- Dividend Yield
- KPRX N/A
- GXAI N/A
- EPS Growth
- KPRX N/A
- GXAI N/A
- EPS
- KPRX N/A
- GXAI N/A
- Revenue
- KPRX $20,000.00
- GXAI $27,740.00
- Revenue This Year
- KPRX N/A
- GXAI N/A
- Revenue Next Year
- KPRX N/A
- GXAI N/A
- P/E Ratio
- KPRX N/A
- GXAI N/A
- Revenue Growth
- KPRX N/A
- GXAI 9987.27
- 52 Week Low
- KPRX $2.51
- GXAI $1.00
- 52 Week High
- KPRX $4.86
- GXAI $7.50
- Technical
- Relative Strength Index (RSI)
- KPRX 43.33
- GXAI 52.14
- Support Level
- KPRX $2.87
- GXAI $1.29
- Resistance Level
- KPRX $3.22
- GXAI $1.37
- Average True Range (ATR)
- KPRX 0.18
- GXAI 0.08
- MACD
- KPRX -0.02
- GXAI -0.01
- Stochastic Oscillator
- KPRX 5.77
- GXAI 46.15
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.